newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis ​​on the management of SE Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a